Continuous Cell Lines Persistently Expressing High Levels of Native HIV-1 Envelope Trimers on their Surface Membrane


Transduced human cell lines expressing high levels of native HIV-1 Envelope on their surface membrane, in the unmodified or interdomain stabilized form. These cell lines provide a stable source of native HIV-1 envelope for multiple uses, including the high-efficiency production of virus-like particles (VLPs) for use as vaccines, testing new inhibitors or neutralizing antibodies, or identifying/capturing B cells that produce broadly neutralizing antibodies from infected/vaccinated humans or animals.

This technology is available for licensing for commercial development in accordance with 35 U.S.C. § 209 and 37 CFR Part 404, as well as for further development and evaluation under a research collaboration.

Potential Commercial Applications: Competitive Advantages:
  • High-efficiency production of virus-like particles (VLPs)
  • A means to test new inhibitors or neutralizing antibodies targeting HIV-1 envelope trimers
  • Probe for identifying/capturing B cells that produce broadly neutralizing antibodies
 
  • The interdomain-stabilized form does not bind CD4 and is locked in the native prefusion form


Inventors:

Paolo Lusso (NIAID)  ➽ more inventions...

Peng Zhang (NIAID)  ➽ more inventions...


Intellectual Property:

Publications:
Zhang, Peng, et al doi 10.1016/j.chom.2018.05.002

Collaboration Opportunity:

The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize this technology. For collaboration opportunities, please contact Chris Kornak at


Licensing Contact:
Christopher Kornak, J.D.
Email: chris.kornak@nih.gov
Phone: 240-627-3705

OTT Reference No: E-185-2018-0
Updated: Mar 9, 2020